Advertisement

Tumor Biology

, Volume 37, Issue 6, pp 8145–8152 | Cite as

Association of the hypermethylation status of PTEN tumor suppressor gene with the risk of breast cancer among Kurdish population from Western Iran

  • Kheirollah Yari
  • Mehrdad Payandeh
  • Zohreh Rahimi
Original Article

Abstract

Breast cancer is the most common cancer with high morbidity and mortality among women worldwide. Aberrant hypermethylation in promoter regions of the tumor suppressor genes such as PTEN gene is a key event in the progression and development of breast cancer. The aim of the present study was to evaluate an association between PTEN gene methylation status with the risk of breast cancer in an Iranian population. We studied 255 individuals, including 103 patients with breast cancer, 102 first-degree female relatives of patients (mother, sister, or daughter of patients), and 50 healthy individuals as a control group. Genomic DNA was extracted from peripheral blood leukocytes, and the PTEN promoter methylation status was detected using methylation-specific PCR (MSP) method with specific methylated and unmethylated primers. In some samples, direct DNA sequencing was used to confirm the results obtained by the MSP method. The frequency of PTEN-methylated (MM) genotype was 6 % in the healthy control group, 23.3 % in relatives of patients, and 41.7 % in patients (χ 2 = 24.62, p < 0.001). There were significant differences in the frequency of PTEN-methylated genotype between healthy control compared to that in patients (χ 2 = 15.1, p < 0.001) and also compared to that in relatives of patients (χ 2 = 6.9, p = 0.009). In the presence of PTEN MM genotype, there was a 3.1-fold susceptibility to breast cancer compared to the UU genotype (p < 0.001). Also, in the presence of PTEN M allele, the risk of breast cancer was 2.71-fold compared to the presence of U allele (p < 0.001). Our findings indicated increased frequency of hypermethylation of PTEN promoter in the studied patients and their relatives that could be considered as one of the epigenetic factors affecting the risk of breast cancer in Iranians.

Keywords

Breast cancer PTEN Methylation Epigenetic Methylation-specific PCR Iranian population 

Notes

Acknowledgments

This work was performed in partial fulfillment of the requirements for PhD by Research of Mr. Kheirolah Yari, Kermanshah University of Medical Sciences, Kermanshah, Iran and was financially supported by a grant (grant number 92396) from the Kermanshah University of Medical Sciences, Office of the Vice Chancellor for Research, Kermanshah, Iran.

References

  1. 1.
    Rahimi Z, Yari K. Matrix metalloproteinase-9-1562t allele and its combination with mmp-2-735 c allele are risk factors for breast cancer. Asian Pacific Journal of Cancer Prevention: APJCP. 2014;16:1175–9.CrossRefGoogle Scholar
  2. 2.
    Rahimi Z, Yari K. Matrix metalloproteinase-9 -1562t allele and its combination with mmp-2 -735 c allele are risk factors for breast cancer. Asian Pacific Journal of Cancer Prevention : APJCP. 2015;16:1175–9.CrossRefPubMedGoogle Scholar
  3. 3.
    Khakpour G, Pooladi A, Izadi P, Noruzinia M, Bazzaz JT. DNA methylation as a promising landscape: a simple blood test for breast cancer prediction. Tumor Biol. 2015;36:4905–12.CrossRefGoogle Scholar
  4. 4.
    Pirouzpanah S, Taleban F-A, Mehdipour P, Atri M. Association of folate and other one-carbon related nutrients with hypermethylation status and expression of rarb, brca1, and rassf1a genes in breast cancer patients. J Mol Med. 2015;93:1–18.CrossRefGoogle Scholar
  5. 5.
    Izadi P, Noruzinia M, Fereidooni F, Mostakhdemine Hosseini Z, Kamali F. Epigenetic marks in estrogen receptor alpha cpg island correlate with some reproductive risk factors in breast cancer. Mol Biol Rep. 2014;41:7607–12.CrossRefPubMedGoogle Scholar
  6. 6.
    Mojaver M, Mokarian F, Kazemi M, Salehi M. Specific taqman allelic discrimination assay for rs1477196 and rs9939609 single nucleotide polymorphisms of fto gene demonstrated that there is no association between these snps and risk of breast cancer in Iranian women. Advanced Biomedical Research. 2015;4:136.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Muggerud AA, Rønneberg JA, Wärnberg F, Botling J, Busato F, Jovanovic J, et al. Frequent aberrant DNA methylation of abcb1, foxc1, ppp2r2b and pten in ductal carcinoma in situ and early invasive breast cancer. Breast Cancer Res. 2010;12:R3.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Conway K, Edmiston SN, May R, Kuan P, Chu H, Bryant C, et al. DNA methylation profiling in the carolina breast cancer study defines cancer subclasses differing in clinicopathologic characteristics and survival. Breast Cancer Res. 2014;16:450.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Jovanovic J, Rønneberg JA, Tost J, Kristensen V. The epigenetics of breast cancer. Mol Biol. 2010;4:242–54.Google Scholar
  10. 10.
    Phuong NTT, Kim SK, Lim SC, Kim HS, Kim TH, Lee KY, et al. Role of pten promoter methylation in tamoxifen-resistant breast cancer cells. Breast Cancer Res Treat. 2011;130:73–83.CrossRefPubMedGoogle Scholar
  11. 11.
    Lubecka-Pietruszewska K, Kaufman-Szymczyk A, Stefanska B, Fabianowska-Majewska K. Folic acid enforces DNA methylation-mediated transcriptional silencing of pten, apc and rarbeta2 tumour suppressor genes in breast cancer. Biochem Biophys Res Commun. 2013;430:623–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Klajic J, Fleischer T, Dejeux E, Edvardsen H, Warnberg F, Bukholm I, et al. Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors. BMC Cancer. 2013;13:456.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Zhang HY, Liang F, Jia ZL, Song ST, Jiang ZF. Pten mutation, methylation and expression in breast cancer patients. Oncol Lett. 2013;6:161–8.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Yin L, Cai W-J, Liu C-X, Chen Y-Z, Hu J-M, Jiang J-F, et al. Analysis of pten methylation patterns in soft tissue sarcomas by mass array spectrometry. 2013.Google Scholar
  15. 15.
    Sun Z, Ji N, Bi M, Wang S, Liu X, Wang Z. Pten gene is infrequently hypermethylated in human esophageal squamous cell carcinoma. Tumor Biol. 2015;36:1–9.Google Scholar
  16. 16.
    Sadeq V, Isar N, Manoochehr T. Association of sporadic breast cancer with pten/mmac1/tep1 promoter hypermethylation. Med Oncol. 2011;28:420–3.CrossRefPubMedGoogle Scholar
  17. 17.
    Hashemi M, Rezaei H, Eskandari-Nasab E, Kaykhaei M-A, Taheri M. Association of promoter methylation and 32-bp deletion of the pten gene with susceptibility to metabolic syndrome. Mol Med Rep. 2013;7:342–6.PubMedGoogle Scholar
  18. 18.
    Yari K, Rahimi Z, Moradi MT. The mmp-2-735 c allele is a risk factor for susceptibility to breast cancer. Asian Pacific Journal of Cancer Prevention: APJCP. 2013;15:6199–203.CrossRefGoogle Scholar
  19. 19.
    Licchesi JD, Herman JG. Methylation-specific pcr. Springer: DNA methylation; 2009. p. 305–23.Google Scholar
  20. 20.
    Khan S, Kumagai T, Vora J, Bose N, Sehgal I, Koeffler PH, et al. Pten promoter is methylated in a proportion of invasive breast cancers. Int J Cancer. 2004;112:407–10.CrossRefPubMedGoogle Scholar
  21. 21.
    García JM, Silva J, Peña C, Garcia V, Rodríguez R, Cruz MA, et al. Promoter methylation of the pten gene is a common molecular change in breast cancer. Genes Chromosom Cancer. 2004;41:117–24.CrossRefPubMedGoogle Scholar
  22. 22.
    Alipour M, Zargar SJ, Safarian S, Fouladdel S, Azizi E, Jafargholizadeh N. The study of DNA methylation of bax gene promoter in breast and colorectal carcinoma cell lines. Iran J Cancer Prev. 2013;6:59.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Gheibi A, Kazemi M, Baradaran A, Akbari M, Salehi M. Study of promoter methylation pattern of 14-3-3 sigma gene in normal and cancerous tissue of breast: a potential biomarker for detection of breast cancer in patients. Advanced Biomedical Research. 2012;1:80.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, et al. Promoter hypermethylation and brca1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000;92:564–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Soria J-C, Lee H-Y, Lee JI, Wang L, Issa J-P, Kemp BL, et al. Lack of pten expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res. 2002;8:1178–84.PubMedGoogle Scholar
  26. 26.
    Izadi P, Noruzinia M, Karimipoor M, Karbassian MH, Akbari MT. Promoter hypermethylation of estrogen receptor alpha gene is correlated to estrogen receptor negativity in Iranian patients with sporadic breast cancer. Cell J. 2012;14:102.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Pirouzpanah S, Taleban FA, Atri M, Abadi A-R, Mehdipour P. The effect of modifiable potentials on hypermethylation status of retinoic acid receptor-beta2 and estrogen receptor-alpha genes in primary breast cancer. Cancer Causes Control. 2010;21:2101–11.CrossRefPubMedGoogle Scholar
  28. 28.
    Turker MS. Gene silencing in mammalian cells and the spread of DNA methylation. Oncogene. 2002;21:5388–93.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Kheirollah Yari
    • 1
  • Mehrdad Payandeh
    • 2
  • Zohreh Rahimi
    • 1
    • 3
  1. 1.Medical Biology Research CenterKermanshah University of Medical SciencesKermanshahIran
  2. 2.Department of Hematology and Medical OncologyKermanshah University of Medical SciencesKermanshahIran
  3. 3.Department of Clinical BiochemistryKermanshah University of Medical SciencesKermanshahIran

Personalised recommendations